Apixaban: Difference between revisions
(Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links) |
(Added AF main page link to See Also) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Pulmonary embolism]], [[DVT]]=== | ===[[Pulmonary embolism]], [[DVT]]=== | ||
*10mg PO twice daily x 7 days, then 5mg BID | *10mg PO twice daily x 7 days, then 5mg BID | ||
| Line 46: | Line 46: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Reversible factor Xa inhibitor→ decreased thrombin synthesis | *Reversible factor Xa inhibitor→ decreased thrombin synthesis | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | ==Indications by Condition== | ||
''The following table is automatically generated from disease/condition pages across WikEM.'' | ''The following table is automatically generated from disease/condition pages across WikEM.'' | ||
{{#ask:[[Has DrugName::Apixaban]] | {{#ask:[[Has DrugName::Apixaban]] | ||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | }} | ||
| Line 70: | Line 69: | ||
*[[Anticoagulant reversal for life-threatening bleeds]] | *[[Anticoagulant reversal for life-threatening bleeds]] | ||
*[[Procedures in patients with coagulopathies]] | *[[Procedures in patients with coagulopathies]] | ||
*[[Atrial fibrillation (main)]] | |||
*[[PE]] | *[[PE]] | ||
*[[DVT]] | *[[DVT]] | ||
| Line 75: | Line 75: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 01:16, 25 March 2026
Administration
- Type: Anticoagulant
- Dosage Forms: tablet
- Dosage Strengths: 2.5mg, 5mg
- Routes of Administration: Oral
- Common Trade Names: Eliquis
Adult Dosing
Pulmonary embolism, DVT
- 10mg PO twice daily x 7 days, then 5mg BID
Stroke prevention in afib
- 5mg PO BID. Reduce the dose to 2.5 mg PO BID if patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
Post-op DVT prophylaxis after hip or knee arthroplasty
- 2.5mg BID
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: No adjustment for DVT/PE treatment. Afib: 2.5mg BID if creatinine >1.5
- Hepatic dosing: No adjustment for mild impairment. Not recommended if severe impairment.
- Decrease dose if concomitant use of CYP3A4 and P-gp efflux dual inhibitors
Contraindications
- Allergy to class/drug
- Active bleeding
Adverse Reactions
Serious
- Major bleeding (GI, muscular, epidural, intracranial, conjunctival, urinary, intraoperative)
- LFT abnormalities
Common
- Easy bruising, hematoma, gingival bleeding, menorrhagia, epistaxis
Pharmacology
- Half-life: 7-16 hours
- Metabolism: Hepatic, mainly CYP3A4
- Excretion: 25% in urine and feces as metabolites; renal excretion accounts for 27%T of total clearance; biliary and direct intestinal excretion contributes to elimination in feces
Mechanism of Action
- Reversible factor Xa inhibitor→ decreased thrombin synthesis
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Atrial fibrillation (main) | 5 mg BID (reduced: 2.5 mg BID if ≥2 of: age ≥80, wt ≤60 kg, Cr ≥1.5) | Anticoagulation (NOAC) | PO | Adult |
| Pulmonary embolism | 10 mg PO BID x1 week, then 5 mg PO BID | Anticoagulation (DOAC) | PO | Adult |
See Also
- Andexanet alfa
- Anticoagulant reversal for life-threatening bleeds
- Procedures in patients with coagulopathies
- Atrial fibrillation (main)
- PE
- DVT